Collagen-induced platelet aggregation blocker revacept - a possible role as a dialysate additive? PDF Print
Circulation: Conclusion— This phase I study demonstrated that Revacept is a safe and well-tolerated new antiplatelet compound with a clear dose-dependent pharmacokinetic profile with specific, dose-related inhibition of platelet aggregation despite completely unaltered general hemostasis.

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.

Notice: Undefined variable: query in /home/globaldi/public_html/components/com_joomlawatch/class.joomlawatch.db.php on line 129